Literature DB >> 17313379

Higher thrombin concentrations are required to induce platelet apoptosis than to induce platelet activation.

V Leytin1, D J Allen, E Lyubimov, J Freedman.   

Abstract

Primarily known as an inducer of blood coagulation and platelet activation, thrombin also triggers platelet apoptosis. This study demonstrated that the platelet activation response is much more sensitive than platelet apoptosis to thrombin treatment. Thrombin concentrations of 0.5-1 nmol/l activated almost all platelets, but only a small fraction underwent apoptosis, suggesting that at these relatively low thrombin concentrations, platelets may perform haemostasis but not be involved in programmed cell death. At high thrombin concentrations of 10-100 nmol/l, generated during blood coagulation, 30-40% of platelets became apoptotic, indicating that hypercoagulable states may be associated with increased numbers of apoptotic platelets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313379     DOI: 10.1111/j.1365-2141.2007.06503.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

Review 1.  Markers of platelet apoptosis: methodology and applications.

Authors:  Armen V Gyulkhandanyan; Asuman Mutlu; John Freedman; Valery Leytin
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

2.  Imbalanced expression of Bcl-xL and Bax in platelets treated with plasma from immune thrombocytopenia.

Authors:  Jianlin Qiao; Yun Liu; Depeng Li; Yulu Wu; Xiaoqian Li; Yao Yao; Mingshan Niu; Chunling Fu; Hongchun Li; Ping Ma; Zhenyu Li; Kailin Xu; Lingyu Zeng
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

3.  State of the art in platelet function testing.

Authors:  Beate E Kehrel; Martin F Brodde
Journal:  Transfus Med Hemother       Date:  2013-03-18       Impact factor: 3.747

4.  The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187.

Authors:  Valery Leytin; Asuman Mutlu; Sergiy Mykhaylov; David J Allen; Armen V Gyulkhandanyan; John Freedman
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

5.  A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil.

Authors:  Paula Yurie Tanaka; Luis Fernando Pracchia; Marcelo Bellesso; Dalton Alencar Fischer Chamone; Edenilson Eduardo Calore; Juliana Pereira
Journal:  Ann Hematol       Date:  2009-06-04       Impact factor: 3.673

6.  Anti-inflammatory actions of aprotinin provide dose-dependent cardioprotection from reperfusion injury.

Authors:  Jm Carter; U Buerke; E Rössner; M Russ; S Schubert; H Schmidt; H Ebelt; D Pruefer; A Schlitt; K Werdan; M Buerke
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

7.  Investigating caspases and other markers of apoptosis in ITP.

Authors:  Oliver Speer; Markus Schmugge
Journal:  Ann Hematol       Date:  2010-04-22       Impact factor: 3.673

8.  Thrombin-induced cytoskeleton dynamics in spread human platelets observed with fast scanning ion conductance microscopy.

Authors:  Jan Seifert; Johannes Rheinlaender; Florian Lang; Meinrad Gawaz; Tilman E Schäffer
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

9.  Protease Activated Receptor 4 as a Novel Modulator of Regulatory T Cell Function.

Authors:  Qi Peng; Kulachelvy Ratnasothy; Dominic A Boardman; Jacinta Jacob; Sim Lai Tung; Daniel McCluskey; Lesley A Smyth; Robert I Lechler; Anthony Dorling; Giovanna Lombardi
Journal:  Front Immunol       Date:  2019-06-18       Impact factor: 7.561

10.  Inducing mitophagy in diabetic platelets protects against severe oxidative stress.

Authors:  Seung Hee Lee; Jing Du; Jeremiah Stitham; Gourg Atteya; Suho Lee; Yaozu Xiang; Dandan Wang; Yu Jin; Kristen L Leslie; Geralyn Spollett; Anup Srivastava; Praveen Mannam; Allison Ostriker; Kathleen A Martin; Wai Ho Tang; John Hwa
Journal:  EMBO Mol Med       Date:  2016-07-01       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.